SG11202109073VA - Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use - Google Patents

Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use

Info

Publication number
SG11202109073VA
SG11202109073VA SG11202109073VA SG11202109073VA SG11202109073VA SG 11202109073V A SG11202109073V A SG 11202109073VA SG 11202109073V A SG11202109073V A SG 11202109073VA SG 11202109073V A SG11202109073V A SG 11202109073VA SG 11202109073V A SG11202109073V A SG 11202109073VA
Authority
SG
Singapore
Prior art keywords
antigen
methods
cells including
erythroid cells
engineered erythroid
Prior art date
Application number
SG11202109073VA
Inventor
Tiffany Chen
Thomas Joseph Wickham
Christopher Lawrence Moore
Shamael Dastagir
Douglas Charles Mclaughlin
Regina Sophia Salvat
Alex Richard Nanna
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of SG11202109073VA publication Critical patent/SG11202109073VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11202109073VA 2019-02-20 2020-02-20 Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use SG11202109073VA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808253P 2019-02-20 2019-02-20
US201962877190P 2019-07-22 2019-07-22
US201962926222P 2019-10-25 2019-10-25
US201962938839P 2019-11-21 2019-11-21
PCT/US2020/019123 WO2020172472A1 (en) 2019-02-20 2020-02-20 Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use

Publications (1)

Publication Number Publication Date
SG11202109073VA true SG11202109073VA (en) 2021-09-29

Family

ID=69960724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109073VA SG11202109073VA (en) 2019-02-20 2020-02-20 Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use

Country Status (12)

Country Link
US (1) US20200291355A1 (en)
EP (1) EP3927354A1 (en)
JP (1) JP2022521738A (en)
KR (1) KR20210135008A (en)
CN (1) CN113795263A (en)
AU (1) AU2020224662A1 (en)
BR (1) BR112021016451A2 (en)
CA (1) CA3130750A1 (en)
IL (1) IL285713A (en)
MX (1) MX2021010089A (en)
SG (1) SG11202109073VA (en)
WO (1) WO2020172472A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507329A (en) * 2017-02-17 2020-03-12 ルビウス セラピューティクス， インコーポレイテッド Functional erythroid cells
EP3679064A4 (en) 2017-09-07 2021-06-02 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
KR102297396B1 (en) * 2020-07-29 2021-09-06 (주)티카로스 Immune Synapse-Stabilizing Chimeric Antigen Receptor(CAR) T Cell
US20240082411A1 (en) * 2020-11-06 2024-03-14 Cue Biopharma, Inc. T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
WO2022144556A1 (en) * 2020-12-31 2022-07-07 Oxford University Innovation Limited Mhc: peptide complexes
EP4368189A1 (en) * 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
WO2002046399A2 (en) 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Mutated class i major histocompatibility proteins and complexes
AU2002220275A1 (en) 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
US7442773B2 (en) 2004-01-23 2008-10-28 The Board Of Trustees Of The University Of Illinois Universal peptide-binding scaffolds and protein chips
WO2007030708A2 (en) 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
KR102447139B1 (en) 2010-05-14 2022-09-23 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
US9574178B2 (en) 2011-03-18 2017-02-21 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
GB201200458D0 (en) 2012-01-11 2012-02-22 Nhs Blood & Transplant Methods of preparing cells and compositions
US8975072B2 (en) 2012-07-20 2015-03-10 Riken Human erythroid progenitor cell line comprising HPV E6/E7 operably linked to an inducible promoter and method for producing human enucleated red blood cells
JP6603209B2 (en) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Protein modification of living cells using sortase
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
AU2014281030B2 (en) * 2013-06-17 2020-07-09 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
JP6702866B2 (en) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド Synthetic membrane-receiver complex
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US10835585B2 (en) 2015-05-20 2020-11-17 The Broad Institute, Inc. Shared neoantigens
RU2729116C2 (en) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Identification, production and use of neoantigens
SG11201805253SA (en) * 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for cancer indications
MA45455A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc PROCESS FOR IDENTIFYING PEPTIDIC EPITOPES, MOLECULES THAT BIND TO SUCH EPITOPES AND ASSOCIATED USES
JP2019520829A (en) 2016-07-07 2019-07-25 ルビウス セラピューティクス， インコーポレイテッド Compositions and methods related to therapeutic cell lines expressing foreign RNA
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2020507329A (en) 2017-02-17 2020-03-12 ルビウス セラピューティクス， インコーポレイテッド Functional erythroid cells
EP3654991A1 (en) * 2017-07-19 2020-05-27 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for infectious disease
WO2019126818A1 (en) 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use

Also Published As

Publication number Publication date
EP3927354A1 (en) 2021-12-29
KR20210135008A (en) 2021-11-12
MX2021010089A (en) 2021-12-10
US20200291355A1 (en) 2020-09-17
IL285713A (en) 2021-10-31
BR112021016451A2 (en) 2021-11-09
JP2022521738A (en) 2022-04-12
WO2020172472A1 (en) 2020-08-27
CN113795263A (en) 2021-12-14
AU2020224662A1 (en) 2021-09-09
CA3130750A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
IL285713A (en) Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
IL272332A (en) Antigen-presenting polypeptides and methods of use thereof
GB201919274D0 (en) Portable and rechargeable blender
IL276523A (en) Modified pluripotent stem cells and methods of making and use
IL291244A (en) Hpk1 antagonists and uses thereof
EP3538561A4 (en) Variant rna-guided polypeptides and methods of use
IL287553B1 (en) Modified pluripotent cells
EP3430132A4 (en) Generation of midbrain-specific organoids from human pluripotent stem cells
IL263265A (en) Use of mesenchymal stem cells and parts thereof
EP3589293A4 (en) Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors
IL275076A (en) Serum-free media formulation for culturing cells and methods of use thereof
IL275037A (en) Crispr-cas9 modified cd34plus human hematopoietic stem and progenitor cells and uses thereof
IL290297A (en) Modified cytotoxic t cells and methods of use thereof
IL277673A (en) Engineered cells and uses thereof
ZA201801503B (en) Formulation of a serum-free medium used for human pluripotent stem cells
SG11202111679XA (en) Engineered cells and uses thereof
SG11202103024RA (en) Culture material and use thereof
SG11202112978WA (en) Auto-injector and related methods of use
GB201908224D0 (en) Improved retinal organoids and methods of making the same
IL263341A (en) Stem cell material, compositions, and methods of use
SG11202109701SA (en) T cell receptors and methods of use thereof
IL289718A (en) Manipulation and use of antigen-specific regulatory t cells
GB201901166D0 (en) Genetic construct and uses thereof
IL287808A (en) Pluripotent cell aggregates and use thereof
IL291180A (en) Bee vaccines and methods of use